Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-003902
Filing Date
2025-04-11
Accepted
2025-04-11 17:29:24
Documents
17
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm   iXBRL DEF 14A 729101
2 proxy_001.jpg GRAPHIC 89960
3 proxy_002.jpg GRAPHIC 56000
  Complete submission text file 0001641172-25-003902.txt   1903958

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE awh-20241231.xsd EX-101.SCH 5715
5 XBRL DEFINITION FILE awh-20241231_def.xml EX-101.DEF 9993
6 XBRL LABEL FILE awh-20241231_lab.xml EX-101.LAB 63819
7 XBRL PRESENTATION FILE awh-20241231_pre.xml EX-101.PRE 44665
20 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 222520
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34810 | Film No.: 25833718
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)